Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Department of Nephrology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China.
Nephron. 2018;139(3):269-282. doi: 10.1159/000487104. Epub 2018 Mar 14.
Renal fibrosis is a common outcome of nearly all kinds of chronic kidney disease (CKD) and eventually progresses to end-stage renal disease. The identification of an optimal biomarker of renal fibrosis to replace the invasive renal biopsy will have important clinical implications.
We isolated urinary exosomes from 50 participants and examined the exosomal protein content and particle number in 38 CKD patients with different degrees of renal fibrosis and in 12 normal individuals. We examined the levels of exosomal microRNAs (miRNAs), namely, miR-200a, miR-200b, miR-200c, miR-141, miR-429, miR-29a, miR-29b, miR-29c, miR-192, and miR-21, by sorting the exosomes and comparing the levels of proximal tubular, non-proximal tubular, and total exosomal miR-200b.
The exosome content was higher in the CKD group, but no differences were evident among the mild, moderate, and severe fibrosis groups. Among the 10 exosomal miRNAs, miR-200b was lower in the CKD group than in the normal group and decreased more significantly with fibrosis progression as well as in IgA nephropathy and diabetic kidney disease. CD13+ CD63+ exosomes constituted 18.6% of all urinary exosomes. Sorting the proximal tubular exosomes with the CD13 protein marker revealed that miR-200b in the CD13+ group was extremely low; however, the result was significantly different in the CD13- group but not in the CD13+ group. The magnitude of the decline was greater in the CD13- groups than in the non-sorted whole groups between the fibrosis and normal patients.
Non-proximal renal tubule-derived urinary exosomal miR-200b is a biomarker of renal fibrosis. Exosomes can be used as a liquid biopsy and may replace the traditional invasive renal biopsy in the diagnosis of renal fibrosis.
肾纤维化是几乎所有类型慢性肾脏病(CKD)的常见后果,最终会进展为终末期肾病。找到一种替代有创性肾活检的肾纤维化最佳生物标志物将具有重要的临床意义。
我们从 50 名参与者中分离尿液外泌体,并在 38 名不同程度肾纤维化的 CKD 患者和 12 名正常个体中检查外泌体蛋白含量和颗粒数。我们通过分选外泌体来检查外泌体 microRNAs(miRNAs)的水平,即 miR-200a、miR-200b、miR-200c、miR-141、miR-429、miR-29a、miR-29b、miR-29c、miR-192 和 miR-21,比较近端肾小管、非近端肾小管和总外泌体 miR-200b 的水平。
CKD 组的外体含量较高,但轻度、中度和重度纤维化组之间没有明显差异。在 10 种外泌体 miRNA 中,miR-200b 在 CKD 组中的含量低于正常组,并且随着纤维化进展以及 IgA 肾病和糖尿病肾病的进展,其下降更为明显。CD13+CD63+外泌体构成所有尿液外泌体的 18.6%。用 CD13 蛋白标志物分选近端肾小管外泌体显示,CD13+组的 miR-200b 极低;然而,在 CD13-组中结果明显不同,但在 CD13+组中则不然。在纤维化患者和正常患者之间,CD13-组的下降幅度大于非分选全组。
非近端肾小管来源的尿液外泌体 miR-200b 是肾纤维化的生物标志物。外泌体可用作液体活检,可能替代传统的有创性肾活检用于诊断肾纤维化。